Roivant (ROIV) was higher in Monday trading as investors revisited the company’s early-April update that highlighted a large liquidity position and ongoing capital returns. In a Form 8-K dated April 2, 2026, Roivant reported preliminary unaudited consolidated cash, cash equivalents and marketable securities of approximately $4.3 billion as of March 31, 2026, and said it repurchased 3,956,362 shares for an aggregate purchase price of about $109.7 million during the quarter. (investor.roivant.com)

The same April 2 disclosure also outlined development momentum for brepocitinib, including a new Phase 2b/3 clinical program in lichen planopilaris and positioning of brepocitinib across multiple late-stage indications. Roivant also stated that the FDA granted Priority Review for brepocitinib’s NDA in dermatomyositis, with a PDUFA target action date in the third quarter of 2026, keeping a major regulatory catalyst on the calendar. (investor.roivant.com)

Roivant’s update included topline results from Immunovant’s two Phase 3 thyroid eye disease studies of batoclimab that failed to meet their primary endpoint, which can act as a sentiment overhang even as focus shifts to IMVT-1402 development plans. Near term, traders are likely to watch for any additional regulatory milestones tied to the dermatomyositis filing, further clarity on upcoming late-2026 data expectations mentioned in the April disclosure, and confirmation of the company’s next earnings timing as the fiscal-year reporting cycle approaches. (investor.roivant.com)